NEW YORK and WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to ...
Dianthus Therapeutics recently reported an early “GO” decision for its late-stage CAPTIVATE study of claseprubart in chronic ...
Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label extension data further supporting potential for 300mg/2mL Q4W dosing Phase ...
(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to ...
Dianthus Therapeutics to present at J.P. Morgan Healthcare Conference on January 15, 2025, discussing antibody therapies for autoimmune diseases. Dianthus Therapeutics, Inc., a clinical-stage ...
NEW YORK and WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results